CDKN2A and cancer: Familial melanoma cases with germline mutations in CDKN2A have younger ages at onset (40 vs. 50 years), have increased numbers of melanoma cases per family, and are more prone to developing multiple melanomas and other cancers, such as pancreatic cancer, compared with familial cases lacking CDKN2A mutations [53,54].